At least four of six different vaccine candidates financially backed by the U.S. government aimed at the novel coronavirus are predicted to fail in the clinic, according to a draft report from an analytics group cited by CNBC.
Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics, and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals, were convicted of insider trading by a federal grand jury in Boston.
